Our Next Pathology Oncology Digital Series:

July 28, 2026

Our Next Pathology
Oncology Digital Series:

July 28, 2026

REGISTER FOR THE NEXT CAMP PODS CLICK HERE

WELCOME

CAMP PODS is a webinar series, consisting of nine one-hour sessions that will take place from January to November 2026 for an hour once a month.

The goal of this series is to build a strong Oncology Laboratory Medicine community, where best practices and common challenges can be discussed.  Insights gained will be key to implement across Canada and will help streamline laboratory workflows and practice for laboratory medicine, the end result of which will be improvements in the patient journey.

Overall Learning Objectives:

By the end of the webinar series, an audience member will:

  1. Establish a strong Oncology Education Network
  2. Compare ideas, thoughts and common challenges
  3. Identify gaps and find team solutions for improving patient care
  4. Integrate pathology and oncology practices

NEXT CAMP PODS SESSION

Tuesday, July 28, 2026
9:00am – 9:50 am PT No Single Tool is Perfect: Tricky Cases Solved By Context-Dependant Approach Abbas Agaimy, MD

Professor & Deputy Director, Institute of Pathology,
Friedrich‐Alexander‐University Erlangen‐Nuremberg,
University Hospital,
Erlangen, Germany
9:50am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Describe the complementary roles of anatomical pathology, immunohistochemistry, and molecular diagnostics in the integrated diagnosis and classification of human cancers.
  2. Apply a multimodal diagnostic approach by selecting and interpreting histomorphologic, immunophenotypic, and molecular findings to optimize diagnostic accuracy and biomarker assessment.
  3. Recognize the strengths, limitations, and appropriate clinical applications of immunohistochemical and molecular testing methodologies in precision oncology.
  4. Integrate morphologic, immunohistochemical, and molecular data into clinically relevant pathology reports that support prognostic stratification, predictive biomarker testing, and personalized treatment decisions within multidisciplinary cancer care.

OUR LAST CAMP PODS SESSION

Wednesday, May 27, 2026
9:00am – 9:45 am PT Indefinite for Dysplasia in Inflammatory Bowel Disease in the Era of Non-Conventional Dysplasia: When Morphology Isn’t Enough Kristen M. Stashek, MD

Gastrointestinal and Liver Pathology
Associate Professor of Clinical Pathology and Laboratory Medicine
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA
9:45am  – 10:00am PT Questions & Answers
Learning objectives:
By the end of this presentation, participants will be able to:

  1. Understand how inflammation induced carcinogenesis impacts the molecular findings seen in IBD dysplastic lesions and adenocarcinomas.
  2. Describe the molecular and histopathologic features of conventional and non conventional dysplasia
  3. Describe the unique PSC/IBD phenotype and its associated dysplasia risk.
  4. Discuss limitations of routine morphology in detecting subtle dysplasia and indications for ancillary diagnostic biomarkers.